Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Artemis Pharmaceuticals GmbH
Cooperation, license agreements signed related to mouse genetics
November 6th, 2004
Artemis Pharmaceuticals GmbH (Cologne) and Boehringer Ingelheim (Ingelheim, Germany and Ridgefield, Connecticut) have signed service and license agreements in the area of mouse genetics and genomics. Under a license agreement Boehringer Ingelheim International GmbH (BII) grants Artemis a worldwide exclusive commercial license and a non-exclusive research license, including sublicensing rights, to its patented "Tetraploid-Technology" for the generation of genetically modified mice. The Tetraploid-Technology is an important addition to Artemis' proprietary ArteMice patent portfolio, as it facilitates the generation of modified mice directly from mouse...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
